影像学技术对肝硬化临床终点事件的预测

王亮; 李永芳; 张岭漪

doi:10.3969/j.issn.1001-5256.2020.09.005

影像学技术对肝硬化临床终点事件的预测

DOI: 10.3969/j.issn.1001-5256.2020.09.005

兰州大学第二医院肝病科

基金项目:

王宝恩肝纤维化研究基金资助(CFHPC2020023)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 1355
- HTML全文浏览量: 51
- PDF下载量: 154
- 被引次数: 0
出版历程
- 收稿日期: 2020-05-18
- 出版日期: 2020-09-20

Value of imaging technology in predicting the clinical end events of liver cirrhosis

Department of Hepatology,Lanzhou University Second Hospital

Research funding:

摘要

摘要: 肝硬化临床终点事件对患者不良影响较大,其中食管胃底静脉曲张、门静脉血栓形成、原发性肝癌等可导致患者生活质量低下甚至死亡。影像学的快速发展为肝硬化临床终点事件的诊断和预测提供了重要参考。基于超声、超声造影、超声内镜、CT、MRI、多层螺旋CT血管成像、数字减影血管造影、核医学检查等影像学手段诊断评估肝硬化临床终点事件极大地为临床医生提供了帮助。然而,不同种类的影像技术具有不同的影像学特征。因此,医生应根据临床需要使用。
- 肝硬化 /
- 诊断显像 /
- 癌,肝细胞 /
- 食管和胃静脉曲张
Abstract: The clinical end events of liver cirrhosis have great adverse influence on patients,among which esophageal and gastric varices,portal vein thrombosis,and primary liver cancer might lead to low quality of life and even death. The rapid development of imaging technology provides an important reference for the diagnosis and prediction of the clinical end events of liver cirrhosis. The imaging methods based on ultrasound,contrast-enhanced ultrasound,endoscopic ultrasound,computed tomography( CT),magnetic resonance imaging,multi-slice spiral CT angiography,digital subtraction angiography,and nuclear medicine examination provide great help for clinicians in the diagnosis and evaluation of the clinical end events of liver cirrhosis. However,different imaging techniques may have different features,and therefore,clinicians should use these techniques based on clinical needs.
- liver cirrhosis /
- diagnostic imaging /
- carcinoma,hepatocellular /
- esophageal and gastric varices

HTML全文

参考文献(37)

[1] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis[J]. J Hepatol,2018,69(2):406-460.

[2] Chinese Society of Hepatology,Chinese Medical Association,XU X,et al. Chinese guidelines on the management of ascites and its related complications in cirrhosis[J]. Hepatol Int,2019,13(1):1-21.

[3] Chinese Society of Hepatology,Chinese Medical Association.Chinese guidelines on the management of liver cirrhosis[J]. J Clin Hepatol,2019,35(11):2408-2425.(in Chinese)中华医学会肝病学分会．肝硬化诊治指南[J]．临床肝胆病杂志，2019,35(11):2408-2425.

[4] YANG HR. Value of color Doppler ultrasound in the diagnosis of portal hypertension liver cirrhosis merged with esophageal variceal bleeding[J]. J Hainan Med Univ,2016,22(5):496-498.(in Chinese)杨海荣．彩色多普勒超声在肝硬化门脉高压食管静脉曲张破裂出血中的价值[J]．海南医学院学报，2016,22(5):496-498.

[5] QI X,BERZIGOTTI A,CARDENAS A,et al. Emerging noninvasive approaches for diagnosis and monitoring of portal hypertension[J]. Lancet Gastroenterol Hepatol,2018,3(10):708-719.

[6] de FRANCHIS R,DELL'ERA A,PRIMIGNANI M. Diagnosis and monitoring of portal hypertension[J]. Dig Liver Dis,2008,40(5):312-317.

[7] HANNA RF,AGUIRRE DA,KASED N,et al. Cirrhosis-associated hepatocellular nodules:Correlation of histopathologic and MR imaging features[J]. Radiographics,2008,28(3):747-769.

[8] PALANIYAPPAN N,COX E,BRADLEY C,et al. Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging[J]. J Hepatol,2016,65(6):1131-1139.

[9] MILLER L,BANSON FL,BAZIR K,et al. Risk of esophageal variceal bleeding based on endoscopic ultrasound evaluation of the sum of esophageal variceal cross-sectional surface area[J]. Am J Gastroenterol,2003,98(2):454-459.

[10] LI S,ZHANG DF,LU W,et al. The predictive value of endoscopic ultrasound for the or the recurrence of esophageal varices after endo-scopic sophageal varix ligation[J]. Chin J Dis Endosc,2016,33(4):223-228.(in chinese)李爽，张德发，陆伟，等．超声内镜对食管静脉曲张套扎术后复发的预测作用[J]．中华消化内镜杂志，2016,33(4):223-228.

[11] MCCOLLOUGH CH,LENG S,YU L,et al. Dual-and multienergy CT:Principles,technical approaches,and clinical applications[J]. Radiology,2015,276(3):637-653.

[12] FORNER A,REIG M,BRUIX J. Hepatocellular carcinoma[J].Lancet,2018,391(10127):1301-1314.

[13] Bureau of Medical Administration,National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China(2019 edition)[J]. J Clin Hepatol,2020,36(2):277-292.(in Chinese)中华人民共和国国家卫生健康委员会医政医管局．原发性肝癌诊疗规范(2019年版)[J]．临床肝胆病杂志，2020,36(2):277-292.

[14] VILLANUEVA A. Hepatocellular carcinoma[J]. N Engl J Med,2019,380(15):1450-1462.

[15] RENZULLI M,BISELLI M,BROCCHI S,et al. New hallmark of hepatocellular carcinoma,early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis:A new diagnostic algorithm[J]. Gut,2018,67(9):1674-1682.

[16] MARRERO JA,KULIK LM,SIRLIN CB,et al. Diagnosis,staging, and management of hepatocellular carcinoma:2018Practice Guidance by the American Association for the Study of Liver Diseases[J]. Hepatology,2018,68(2):723-50.

[17] ZHOU XM,LIU CC,ZHOU W,et al. An excerpt of ACR appropriateness criteria chronic liver disease(2017)[J]. J Clin Hepatol,2018,34(1):44-45.(in Chinese)周新苗，刘长春，周巍，等．《2017年美国放射学会慢性肝病放射诊断的适用标准》摘译[J]．临床肝胆病杂志，2018,34(1):44-45.

[18] ROBERTS LR,SIRLIN CB,ZAIEM F,et al. Imaging for the diagnosis of hepatocellular carcinoma:A systematic review and meta-analysis[J]. Hepatology,2018,67(1):401-421.

[19] PARK JW,KIM JH,KIM SK,et al. A prospective evaluation of18F-FDG and 11C-acetate PET/CT for detection of primary and metastatic hepatocellular carcinoma[J]. J Nucl Med,2008,49(12):1912-1921.

[20] LIN CY,CHEN JH,LIANG JA,et al.18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma:A systematic review and meta-analysis[J]. Eur J Radiol,2012,81(9):2417-2422.

[21] BELLAARD R,DELGADO-BOLTON R,OYEN WJ,et al.FDG PET/CT:EANM procedure guidelines for tumour imaging:version 2. 0[J]. Eur J Nucl Med Mol Imaging,2015,43(2):328-354.

[22] NA SJ,OH JK,HYUN SH,et al.(18)-FDG PET/CT can prediat surival of advanced hepatocellular carcinoma patients:A multicenter retrospective cohort study[J]. J Nucl Mecl,2017,58(5):730-736.

[23] HECTORS SJ,WAGNER M,BESA C,et al. Multiparametric FDG-PET/MRI of hepatocellular carcinoma:Initial experience[J]. Contrast Media Mol Imaging,2018,2018:5638283.

[24] MARGINI C,BERZIGOTTI A. Portal vein thrombosis:The role of imaging in the clinical setting[J]. Dig Liver Dis,2017,49(2):113-120.

[25] SARIN SK,PHILIPS CA,KAMATH PS,et al. Toward a comprehensive new classification of portal vein thrombosis in patients with cirrhosis[J]. Gastroenterology,2016,151(4):574-577,e3.

[26] SHIMADA K,ISODA H,OKADA T,et al. Non-contrast-enhanced MR portography with time-spatial labeling inversion pulses:Comparison of imaging with three-dimensional halffourier fast spin-echo and true steady-state free-precession sequences[J]. J Magn Reson Imaging,2009,29(5):1140-1146.

[27] FURUTA A,ISODA H,YAMASHITA R,et al. Non-contrastenhanced MR portography with balanced steady-state freeprecession sequence and time-spatial labeling inversion pulses:Comparison of imaging with flow-in and flow-out methods[J]. J Magn Reson Imaging,2014,40(3):583-587.

[28] OHNO T,ISODA H,FURUTA A,et al. Non-contrast-enhanced MR portography and hepatic venography with timespatial labeling inversion pulses:Comparison at 1. 5 Tesla and3 Tesla[J]. Acta Radiol Open, 2015, 4(5):2058460115584110.

[29] LYU Y,HAN GH,FAN DM. Research progress of portal vein thrombosis in patients with liver cirrhosis[J]. Chin J Dig,2017,37(8):568-570.(in chinese)吕勇，韩国宏，樊代明．肝硬化门静脉血栓研究进展[J]．中华消化杂志，2017,37(8):568-570.

[30] SAPISOCHIN G,BRUIX J. Liver transplantation for hepatocellular carcinoma:Outcomes and novel surgical approaches[J]. Nat Rev Gastroenterol Hepatol,2017,14(4):203-217.

[31] LLOVET JM,PAVEL M,RIMOLA J,et al. Pilot study of living donor liver transplantation for patients with hepatocellular carcinoma exceeding Milan Criteria(Barcelona Clinic Liver Cancer extended criteria)[J]. Liver Transpl,2018,24(3):369-379.

[32] SPOSITO C,CUCCHETTI A,MAZZAFERRO V. Assessing competing risks for death following liver transplantation for hepatocellular carcinoma[J]. Dig Dis Sci,2019,64(4):1001-1007.

[33] ROSSANO G,MARTINA P,GIUSEPPE C,et al. Imaging of liver transplantation[J]. Eur J Radiol,2017,93:295-307.

[34] GIROMETTI R,PANCOT M,COMO G,et al. Imaging of liver transplantation[J]. Eur J Radiol,2017,93:295-307.

[35] RENNET J,DORNIA C,GEORGIEVA M,et al. Identification of early complications following liver transplantation using contrast enhanced ulrasound(CEUS),First results[J]. J Gastrointesti Liver Dis,2012,21:407-412.

[36] WANG WP,HUANG BJ,DING H,et al. Preliminary application of contrast-enhanced ultrasound in detecting hepatic arterial embolization in liver transplantation[J]. Shanghai med imaging technol,2006,15(4):272-273.(in Chinese)王文平，黄备建，丁红，等．超声造影在检测移植肝肝动脉栓塞中的初步应用[J]．上海医学影像技术，2006,15(4):272-273.

[37] HWANG J,KIM YK,JEONG WK,et al. Nonhypervascular hypointense nodules at gadoxetic acid-enhanced MR imaging in chronic liver disease:Diffusion-weighted imaging for characterization[J]. Radiology,2015,276(1):137-146.

施引文献

资源附件(0)

访问统计